Paper Details

  1. Home
  2. Paper Details

Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.

Author: ChenTielong, FangXiaojiang, HuangJinyu, XuXiaoqun, ZhaoQian, ZhengJianwu, ZhuHouyong

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ranolazine improved myocardial perfusion reserve index (MPRI) in patients with definite coronary microvascular dysfunction and subendocardial midventricular MPRI in those with suspicious coronary microvascular dysfunction. Nicorandil reduced the index of microvascular resistance. Both ranolazine and ivabradine reduced angina. Further research is needed to determine the most sensitive indicators of coronary microvascular function.
Paper Details　
Original Abstract of the Article :
PURPOSE: The goal of this study was to investigate the effects of the antianginal drugs ranolazine, nicorandil, and ivabradine on coronary microvascular function. METHODS: Electronic scientific databases were searched for randomized trials investigating the effects of antianginal drugs on coronary ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2019.08.008

データ提供：米国国立医学図書館（NLM）

Antianginal Drugs and Coronary Microvascular Function: A Journey Through the Desert of Heart Health

Nonobstructive coronary artery disease (NOCAD) is a condition that can affect coronary microvascular function, impacting blood flow to the heart. Imagine this condition as a desert landscape, where the vital flow of blood to the heart is hindered. This research explores the effects of antianginal drugs on coronary microvascular function in patients with NOCAD, seeking to find solutions for improving heart health in this challenging environment.

Searching for Oasis in the Desert of Heart Health

This meta-analysis investigates the effects of three antianginal drugs – ranolazine, nicorandil, and ivabradine – on coronary microvascular function. The researchers sought to determine if these drugs could improve blood flow to the heart and alleviate angina symptoms, akin to finding a source of relief and healing in the heart of the desert.

A Glimpse of Hope in the Desert

The findings suggest that while these drugs may not significantly improve coronary flow reserve (CFR) in all patients with NOCAD, they can improve other measures of microvascular function, such as myocardial perfusion reserve index (MPRI) and index of microvascular resistance (IMR). This is like finding different oases within the desert, each offering unique benefits for heart health. The findings highlight the potential of antianginal drugs to improve blood flow and alleviate symptoms in specific subgroups of patients with NOCAD, offering a glimmer of hope for those navigating this challenging landscape.

Dr. Camel's Conclusion

This research provides valuable insights into the complex relationship between antianginal drugs and coronary microvascular function in patients with NOCAD. The study highlights the need for individualized treatment approaches and a comprehensive understanding of the potential benefits and limitations of these medications. This research reminds us that even in the vast and unforgiving desert of heart disease, there is always the potential for progress and improved outcomes.
Date :
  1. Date Completed 2020-06-30
  2. Date Revised 2020-06-30
Further Info :

Pubmed ID

31548105

DOI: Digital Object Identifier

10.1016/j.clinthera.2019.08.008

Related Literature

Article Analysis
・Effects of ranolazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.